ID   SRPK2_HUMAN             Reviewed;         688 AA.
AC   P78362; A8MVX2; O75220; O75221; Q6NUL0; Q6V1X2; Q8IYQ3;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 3.
DT   15-MAR-2017, entry version 163.
DE   RecName: Full=SRSF protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=SFRS protein kinase 2;
DE   AltName: Full=Serine/arginine-rich protein-specific kinase 2;
DE            Short=SR-protein-specific kinase 2;
DE   Contains:
DE     RecName: Full=SRSF protein kinase 2 N-terminal;
DE   Contains:
DE     RecName: Full=SRSF protein kinase 2 C-terminal;
GN   Name=SRPK2 {ECO:0000312|EMBL:AAH68547.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC05299.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND SUBCELLULAR LOCATION.
RC   TISSUE=Fetal brain {ECO:0000269|PubMed:9472028};
RX   PubMed=9472028; DOI=10.1083/jcb.140.4.737;
RA   Wang H.-Y., Lin W., Dyck J.A., Yeakley J.M., Songyang Z.,
RA   Cantley L.C., Fu X.-D.;
RT   "SRPK2: a differentially expressed SR protein-specific kinase involved
RT   in mediating the interaction and localization of pre-mRNA splicing
RT   factors in mammalian cells.";
RL   J. Cell Biol. 140:737-750(1998).
RN   [2] {ECO:0000312|EMBL:AAC29141.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [3] {ECO:0000312|EMBL:AAQ63886.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000312|EMBL:AAH35214.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1-99 (ISOFORM 2).
RC   TISSUE=Retinoblastoma, Skin {ECO:0000312|EMBL:AAH35214.1}, and
RC   Testis {ECO:0000312|EMBL:AAH68547.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5] {ECO:0000312|EMBL:AAQ63886.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-537 (ISOFORM 1).
RC   TISSUE=Testis {ECO:0000312|EMBL:AAQ63886.1};
RA   Sha J.H., Zhou Z.M., Li J.M.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6] {ECO:0000305}
RP   FUNCTION IN PHOSPHORYLATION OF HEPATITIS B VIRUS CORE PROTEIN.
RX   PubMed=12134018; DOI=10.1128/JVI.76.16.8124-8137.2002;
RA   Daub H., Blencke S., Habenberger P., Kurtenbach A., Dennenmoser J.,
RA   Wissing J., Ullrich A., Cotten M.;
RT   "Identification of SRPK1 and SRPK2 as the major cellular protein
RT   kinases phosphorylating hepatitis B virus core protein.";
RL   J. Virol. 76:8124-8137(2002).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [8]
RP   FUNCTION IN NEGATIVE REGULATION OF HEPATITIS B VIRUS (HBV)
RP   REPLICATION.
RX   PubMed=16122776; DOI=10.1016/j.virol.2005.07.030;
RA   Zheng Y., Fu X.D., Ou J.H.;
RT   "Suppression of hepatitis B virus replication by SRPK1 and SRPK2 via a
RT   pathway independent of the phosphorylation of the viral core
RT   protein.";
RL   Virology 342:150-158(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-497, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF ACIN1, AND INTERACTION WITH ACIN1.
RX   PubMed=18559500; DOI=10.1158/0008-5472.CAN-08-0021;
RA   Jang S.W., Yang S.J., Ehlen A., Dong S., Khoury H., Chen J.,
RA   Persson J.L., Ye K.;
RT   "Serine/arginine protein-specific kinase 2 promotes leukemia cell
RT   proliferation by phosphorylating acinus and regulating cyclin A1.";
RL   Cancer Res. 68:4559-4570(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF DDX23/PRP28, AND ASSOCIATION WITH
RP   U4/U6-U5 TRI-SNRNPS.
RX   PubMed=18425142; DOI=10.1038/nsmb.1415;
RA   Mathew R., Hartmuth K., Moehlmann S., Urlaub H., Ficner R.,
RA   Luehrmann R.;
RT   "Phosphorylation of human PRP28 by SRPK2 is required for integration
RT   of the U4/U6-U5 tri-snRNP into the spliceosome.";
RL   Nat. Struct. Mol. Biol. 15:435-443(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-494 AND SER-497, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   FUNCTION, PHOSPHORYLATION AT THR-492 BY PKB/AKT1, AND INTERACTION WITH
RP   PKB/AKT1; YWHAB; YWHAE AND SFN.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380; SER-494 AND
RP   SER-497, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF SRSF2, AND SUBCELLULAR LOCATION.
RX   PubMed=21157427; DOI=10.1038/emboj.2010.333;
RA   Edmond V., Moysan E., Khochbin S., Matthias P., Brambilla C.,
RA   Brambilla E., Gazzeri S., Eymin B.;
RT   "Acetylation and phosphorylation of SRSF2 control cell fate decision
RT   in response to cisplatin.";
RL   EMBO J. 30:510-523(2011).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=21205200; DOI=10.1111/j.1742-4658.2010.07987.x;
RA   Giannakouros T., Nikolakaki E., Mylonis I., Georgatsou E.;
RT   "Serine-arginine protein kinases: a small protein kinase family with a
RT   large cellular presence.";
RL   FEBS J. 278:570-586(2011).
RN   [21]
RP   FUNCTION, CASPASE-3 CLEAVAGE AT ASP-139 AND ASP-403, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21056976; DOI=10.1074/jbc.M110.193441;
RA   Hong Y., Jang S.W., Ye K.;
RT   "The N-terminal fragment from caspase-cleaved serine/arginine protein-
RT   specific kinase2 (SRPK2) translocates into the nucleus and promotes
RT   apoptosis.";
RL   J. Biol. Chem. 286:777-786(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-494 AND SER-497, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-494, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52; SER-380 AND SER-497,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-43; ASP-243; PRO-426; PHE-486 AND
RP   THR-515.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/arginine-rich protein-specific kinase which
CC       specifically phosphorylates its substrates at serine residues
CC       located in regions rich in arginine/serine dipeptides, known as RS
CC       domains and is involved in the phosphorylation of SR splicing
CC       factors and the regulation of splicing. Promotes neuronal
CC       apoptosis by up-regulating cyclin-D1 (CCND1) expression. This is
CC       done by the phosphorylation of SRSF2, leading to the suppression
CC       of p53/TP53 phosphorylation thereby relieving the repressive
CC       effect of p53/TP53 on cyclin-D1 (CCND1) expression. Phosphorylates
CC       ACIN1, and redistributes it from the nuclear speckles to the
CC       nucleoplasm, resulting in cyclin A1 but not cyclin A2 up-
CC       regulation. Plays an essential role in spliceosomal B complex
CC       formation via the phosphorylation of DDX23/PRP28. Can mediate
CC       hepatitis B virus (HBV) core protein phosphorylation. Plays a
CC       negative role in the regulation of HBV replication through a
CC       mechanism not involving the phosphorylation of the core protein
CC       but by reducing the packaging efficiency of the pregenomic RNA
CC       (pgRNA) without affecting the formation of the viral core
CC       particles. {ECO:0000269|PubMed:12134018,
CC       ECO:0000269|PubMed:16122776, ECO:0000269|PubMed:18425142,
CC       ECO:0000269|PubMed:18559500, ECO:0000269|PubMed:19592491,
CC       ECO:0000269|PubMed:21056976, ECO:0000269|PubMed:21157427,
CC       ECO:0000269|PubMed:9472028}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:12134018, ECO:0000269|PubMed:9472028}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12134018,
CC         ECO:0000269|PubMed:9472028};
CC   -!- ENZYME REGULATION: Activated by phosphorylation on Ser-52 and Ser-
CC       588. {ECO:0000250|UniProtKB:Q96SB4}.
CC   -!- SUBUNIT: Interacts with PKB/AKT1 in a phosphorylation-dependent
CC       manner. The phosphorylated form (by PKB/AKT1) interacts with YWHAB
CC       and YWHAE. Interaction with YWHAB suppresses its cleavage by
CC       caspases and inhibits the release of its N-terminal pro-apoptotic
CC       fragment. Interacts with SFN. Associates with U4/U6-U5 tri-small
CC       nuclear ribonucleoproteins (U4/U6-U5 tri-snRNPs).
CC       {ECO:0000269|PubMed:18559500, ECO:0000269|PubMed:19592491}.
CC   -!- INTERACTION:
CC       Q08117:AES; NbExp=3; IntAct=EBI-593303, EBI-717810;
CC       Q9NWB6:ARGLU1; NbExp=2; IntAct=EBI-593303, EBI-2808785;
CC       P49760:CLK2; NbExp=3; IntAct=EBI-593303, EBI-750020;
CC       P49761:CLK3; NbExp=4; IntAct=EBI-593303, EBI-745579;
CC       P51116:FXR2; NbExp=3; IntAct=EBI-593303, EBI-740459;
CC       P07910:HNRNPC; NbExp=2; IntAct=EBI-593303, EBI-357966;
CC       Q9NQ29:LUC7L; NbExp=2; IntAct=EBI-593303, EBI-473747;
CC       Q9Y383:LUC7L2; NbExp=2; IntAct=EBI-593303, EBI-352851;
CC       Q9P127:LUZP4; NbExp=3; IntAct=EBI-593303, EBI-10198848;
CC       Q9BU76:MMTAG2; NbExp=2; IntAct=EBI-593303, EBI-742459;
CC       Q8NAV1:PRPF38A; NbExp=5; IntAct=EBI-593303, EBI-715374;
CC       Q86U06:RBM23; NbExp=2; IntAct=EBI-593303, EBI-780319;
CC       Q14498:RBM39; NbExp=9; IntAct=EBI-593303, EBI-395290;
CC       Q9Y5S9:RBM8A; NbExp=2; IntAct=EBI-593303, EBI-447231;
CC       D3DU92:RNPS1; NbExp=3; IntAct=EBI-593303, EBI-10176640;
CC       Q15287:RNPS1; NbExp=3; IntAct=EBI-593303, EBI-395959;
CC       Q8TAD8:SNIP1; NbExp=3; IntAct=EBI-593303, EBI-749336;
CC       Q8WVK2:SNRNP27; NbExp=5; IntAct=EBI-593303, EBI-2512550;
CC       P08621:SNRNP70; NbExp=3; IntAct=EBI-593303, EBI-1049228;
CC       Q16629:SRSF7; NbExp=2; IntAct=EBI-593303, EBI-398885;
CC       Q9BRL6:SRSF8; NbExp=2; IntAct=EBI-593303, EBI-6380719;
CC       P62995:TRA2B; NbExp=3; IntAct=EBI-593303, EBI-725485;
CC       Q01081:U2AF1; NbExp=7; IntAct=EBI-593303, EBI-632461;
CC       Q01081-2:U2AF1; NbExp=3; IntAct=EBI-593303, EBI-10176676;
CC       P26368:U2AF2; NbExp=4; IntAct=EBI-593303, EBI-742339;
CC       Q96MU7:YTHDC1; NbExp=3; IntAct=EBI-593303, EBI-2849854;
CC       P31946:YWHAB; NbExp=2; IntAct=EBI-593303, EBI-359815;
CC       Q15696:ZRSR2; NbExp=6; IntAct=EBI-593303, EBI-6657923;
CC       O15535:ZSCAN9; NbExp=5; IntAct=EBI-593303, EBI-751531;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles between
CC       the nucleus and the cytoplasm. KAT5/TIP60 inhibits its nuclear
CC       translocation. Phosphorylation at Thr-492 by PKB/AKT1 promotes
CC       nuclear translocation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78362-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78362-2; Sequence=VSP_039386;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, moderately
CC       expressed in heart and skeletal muscle and at low levels in lung,
CC       liver, and kidney. {ECO:0000269|PubMed:9472028}.
CC   -!- PTM: Phosphorylation at Thr-492 by PKB/AKT1 enhances its
CC       stimulatory activity in triggering cyclin-D1 (CCND1) expression
CC       and promoting apoptosis in neurons, which can be blocked by YWHAB.
CC       It also enhances its protein kinase activity toward ACIN1 and
CC       SRSF2, promotes its nuclear translocation and prevents its
CC       proteolytic cleavage. {ECO:0000269|PubMed:19592491}.
CC   -!- PTM: Proteolytically cleaved at Asp-139 and Asp-403 by caspase-3
CC       during apoptotic cell death. Cleavage at Asp-139 which is the
CC       major site of cleavage, produces a small N-terminal fragment that
CC       translocates into nucleus and promotes VP16-induced apoptosis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ63886.1; Type=Miscellaneous discrepancy; Note=The cDNA appears to contain a duplicated region.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U88666; AAC05299.1; -; mRNA.
DR   EMBL; AC005070; AAC29140.1; -; Genomic_DNA.
DR   EMBL; AC005070; AAC29141.1; -; Genomic_DNA.
DR   EMBL; AC004884; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073138; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471070; EAW83359.1; -; Genomic_DNA.
DR   EMBL; BC035214; AAH35214.1; -; mRNA.
DR   EMBL; BC068547; AAH68547.1; -; mRNA.
DR   EMBL; BE781215; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AY354201; AAQ63886.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS34724.1; -. [P78362-2]
DR   CCDS; CCDS5735.1; -. [P78362-1]
DR   RefSeq; NP_001265202.1; NM_001278273.1. [P78362-1]
DR   RefSeq; NP_872633.1; NM_182691.2. [P78362-1]
DR   RefSeq; NP_872634.1; NM_182692.2. [P78362-2]
DR   RefSeq; XP_016868055.1; XM_017012566.1. [P78362-1]
DR   UniGene; Hs.285197; -.
DR   PDB; 2X7G; X-ray; 2.50 A; A=51-688.
DR   PDBsum; 2X7G; -.
DR   ProteinModelPortal; P78362; -.
DR   SMR; P78362; -.
DR   BioGrid; 112611; 449.
DR   IntAct; P78362; 243.
DR   MINT; MINT-1468300; -.
DR   STRING; 9606.ENSP00000377262; -.
DR   BindingDB; P78362; -.
DR   ChEMBL; CHEMBL5668; -.
DR   DrugBank; DB00173; Adenine.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB02733; Purvalanol.
DR   GuidetoPHARMACOLOGY; 2209; -.
DR   iPTMnet; P78362; -.
DR   PhosphoSitePlus; P78362; -.
DR   DMDM; 300669676; -.
DR   EPD; P78362; -.
DR   MaxQB; P78362; -.
DR   PaxDb; P78362; -.
DR   PeptideAtlas; P78362; -.
DR   PRIDE; P78362; -.
DR   DNASU; 6733; -.
DR   Ensembl; ENST00000357311; ENSP00000349863; ENSG00000135250. [P78362-1]
DR   Ensembl; ENST00000393651; ENSP00000377262; ENSG00000135250. [P78362-2]
DR   Ensembl; ENST00000489828; ENSP00000419791; ENSG00000135250. [P78362-1]
DR   GeneID; 6733; -.
DR   KEGG; hsa:6733; -.
DR   UCSC; uc003vct.5; human. [P78362-1]
DR   CTD; 6733; -.
DR   DisGeNET; 6733; -.
DR   GeneCards; SRPK2; -.
DR   H-InvDB; HIX0006976; -.
DR   HGNC; HGNC:11306; SRPK2.
DR   HPA; HPA015522; -.
DR   HPA; HPA020876; -.
DR   MIM; 602980; gene.
DR   neXtProt; NX_P78362; -.
DR   OpenTargets; ENSG00000135250; -.
DR   PharmGKB; PA36130; -.
DR   eggNOG; KOG1290; Eukaryota.
DR   eggNOG; ENOG410XRBH; LUCA.
DR   GeneTree; ENSGT00530000063566; -.
DR   HOVERGEN; HBG108512; -.
DR   InParanoid; P78362; -.
DR   KO; K08831; -.
DR   OMA; NDQDGEY; -.
DR   OrthoDB; EOG091G05H9; -.
DR   PhylomeDB; P78362; -.
DR   TreeFam; TF105334; -.
DR   SignaLink; P78362; -.
DR   SIGNOR; P78362; -.
DR   ChiTaRS; SRPK2; human.
DR   EvolutionaryTrace; P78362; -.
DR   GeneWiki; SRPK2; -.
DR   GenomeRNAi; 6733; -.
DR   PRO; PR:P78362; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000135250; -.
DR   CleanEx; HS_SRPK2; -.
DR   ExpressionAtlas; P78362; baseline and differential.
DR   Genevisible; P78362; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0071889; F:14-3-3 protein binding; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IC:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:BHF-UCL.
DR   GO; GO:0035063; P:nuclear speck organization; ISS:BHF-UCL.
DR   GO; GO:0045787; P:positive regulation of cell cycle; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048024; P:regulation of mRNA splicing, via spliceosome; TAS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IDA:UniProtKB.
DR   GO; GO:0000245; P:spliceosomal complex assembly; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Differentiation; Kinase; mRNA processing; mRNA splicing;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    688       SRSF protein kinase 2.
FT                                /FTId=PRO_0000086677.
FT   CHAIN         1    139       SRSF protein kinase 2 N-terminal.
FT                                /FTId=PRO_0000414751.
FT   CHAIN       140    688       SRSF protein kinase 2 C-terminal.
FT                                /FTId=PRO_0000414752.
FT   DOMAIN       81    684       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      87     95       ATP. {ECO:0000250|UniProtKB:Q9UPE1,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE    214    214       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     110    110       ATP. {ECO:0000250|UniProtKB:Q9UPE1,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   SITE        139    140       Cleavage; by caspase-3.
FT   SITE        403    404       Cleavage; by caspase-3.
FT   MOD_RES      52     52       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     380    380       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     475    475       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54781}.
FT   MOD_RES     478    478       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:O54781}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54781}.
FT   MOD_RES     486    486       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54781}.
FT   MOD_RES     490    490       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O54781}.
FT   MOD_RES     492    492       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:19592491}.
FT   MOD_RES     494    494       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     497    497       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     588    588       Phosphoserine; by CK2. {ECO:0000250}.
FT   VAR_SEQ       1     13       MSVNSEKSSSSER -> MSSRKVLAIQARKRRPKREKHPKK
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039386.
FT   VARIANT      43     43       P -> L (in dbSNP:rs34699980).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041114.
FT   VARIANT     243    243       G -> D (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041115.
FT   VARIANT     426    426       T -> P (in dbSNP:rs55743527).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041116.
FT   VARIANT     486    486       S -> F (in dbSNP:rs56112661).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041117.
FT   VARIANT     515    515       P -> T (in dbSNP:rs56017595).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041118.
FT   VARIANT     608    608       S -> N (in dbSNP:rs1050413).
FT                                /FTId=VAR_060390.
FT   VARIANT     615    615       L -> I (in dbSNP:rs1050418).
FT                                /FTId=VAR_057111.
FT   CONFLICT    137    137       P -> R (in Ref. 4; AAH68547).
FT                                {ECO:0000305}.
FT   CONFLICT    236    237       AT -> P (in Ref. 1; AAC05299).
FT                                {ECO:0000305}.
FT   CONFLICT    521    521       A -> R (in Ref. 1; AAC05299).
FT                                {ECO:0000305}.
FT   CONFLICT    601    601       H -> L (in Ref. 2; AAC29141).
FT                                {ECO:0000305}.
FT   CONFLICT    608    609       SI -> KV (in Ref. 2; AAC29141).
FT                                {ECO:0000305}.
FT   CONFLICT    612    616       HFALS -> KYAML (in Ref. 2; AAC29141).
FT                                {ECO:0000305}.
FT   CONFLICT    621    621       R -> K (in Ref. 2; AAC29141).
FT                                {ECO:0000305}.
FT   CONFLICT    625    627       NRR -> TRK (in Ref. 2; AAC29141).
FT                                {ECO:0000305}.
FT   CONFLICT    640    640       S -> G (in Ref. 4; AAH68547).
FT                                {ECO:0000305}.
FT   CONFLICT    681    681       Missing (in Ref. 1; AAC05299).
FT                                {ECO:0000305}.
FT   TURN         78     80       {ECO:0000244|PDB:2X7G}.
FT   STRAND       81     89       {ECO:0000244|PDB:2X7G}.
FT   STRAND       91    100       {ECO:0000244|PDB:2X7G}.
FT   TURN        101    104       {ECO:0000244|PDB:2X7G}.
FT   STRAND      105    112       {ECO:0000244|PDB:2X7G}.
FT   HELIX       116    134       {ECO:0000244|PDB:2X7G}.
FT   HELIX       140    144       {ECO:0000244|PDB:2X7G}.
FT   STRAND      150    156       {ECO:0000244|PDB:2X7G}.
FT   STRAND      159    166       {ECO:0000244|PDB:2X7G}.
FT   HELIX       173    179       {ECO:0000244|PDB:2X7G}.
FT   TURN        180    182       {ECO:0000244|PDB:2X7G}.
FT   HELIX       187    206       {ECO:0000244|PDB:2X7G}.
FT   HELIX       217    219       {ECO:0000244|PDB:2X7G}.
FT   STRAND      220    222       {ECO:0000244|PDB:2X7G}.
FT   HELIX       226    233       {ECO:0000244|PDB:2X7G}.
FT   HELIX       518    520       {ECO:0000244|PDB:2X7G}.
FT   TURN        521    523       {ECO:0000244|PDB:2X7G}.
FT   STRAND      526    528       {ECO:0000244|PDB:2X7G}.
FT   HELIX       531    533       {ECO:0000244|PDB:2X7G}.
FT   HELIX       548    550       {ECO:0000244|PDB:2X7G}.
FT   HELIX       553    557       {ECO:0000244|PDB:2X7G}.
FT   HELIX       564    579       {ECO:0000244|PDB:2X7G}.
FT   HELIX       594    606       {ECO:0000244|PDB:2X7G}.
FT   HELIX       611    614       {ECO:0000244|PDB:2X7G}.
FT   HELIX       620    623       {ECO:0000244|PDB:2X7G}.
FT   STRAND      630    632       {ECO:0000244|PDB:2X7G}.
FT   HELIX       641    649       {ECO:0000244|PDB:2X7G}.
FT   HELIX       653    666       {ECO:0000244|PDB:2X7G}.
FT   HELIX       671    673       {ECO:0000244|PDB:2X7G}.
FT   HELIX       677    681       {ECO:0000244|PDB:2X7G}.
FT   HELIX       684    686       {ECO:0000244|PDB:2X7G}.
SQ   SEQUENCE   688 AA;  77527 MW;  ACCAF2A887444EC2 CRC64;
     MSVNSEKSSS SERPEPQQKA PLVPPPPPPP PPPPPPLPDP TPPEPEEEIL GSDDEEQEDP
     ADYCKGGYHP VKIGDLFNGR YHVIRKLGWG HFSTVWLCWD MQGKRFVAMK VVKSAQHYTE
     TALDEIKLLK CVRESDPSDP NKDMVVQLID DFKISGMNGI HVCMVFEVLG HHLLKWIIKS
     NYQGLPVRCV KSIIRQVLQG LDYLHSKCKI IHTDIKPENI LMCVDDAYVR RMAAEATEWQ
     KAGAPPPSGS AVSTAPQQKP IGKISKNKKK KLKKKQKRQA ELLEKRLQEI EELEREAERK
     IIEENITSAA PSNDQDGEYC PEVKLKTTGL EEAAEAETAK DNGEAEDQEE KEDAEKENIE
     KDEDDVDQEL ANIDPTWIES PKTNGHIENG PFSLEQQLDD EDDDEEDCPN PEEYNLDEPN
     AESDYTYSSS YEQFNGELPN GRHKIPESQF PEFSTSLFSG SLEPVACGSV LSEGSPLTEQ
     EESSPSHDRS RTVSASSTGD LPKAKTRAAD LLVNPLDPRN ADKIRVKIAD LGNACWVHKH
     FTEDIQTRQY RSIEVLIGAG YSTPADIWST ACMAFELATG DYLFEPHSGE DYSRDEDHIA
     HIIELLGSIP RHFALSGKYS REFFNRRGEL RHITKLKPWS LFDVLVEKYG WPHEDAAQFT
     DFLIPMLEMV PEKRASAGEC LRHPWLNS
//
